Prosecution Insights
Last updated: April 19, 2026

Examiner: RAHMANI, NILOOFAR

Tech Center 1600 • Art Units: 1621 1625 1634 1691

This examiner grants 77% of resolved cases

Performance Statistics

77.2%
Allow Rate
+17.2% vs TC avg
1140
Total Applications
-2.9%
Interview Lift
764
Avg Prosecution Days
Based on 1128 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
25.2%
§102 Novelty
12.6%
§103 Obviousness
35.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18030685 PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE Non-Final OA AMGEN INC.
18566008 COMPOSITIONS OF CLOFAZIMINE AND AMIKACIN FOR PULMONARY ADMINISTRATION IN THE TREATMENT OF RESPIRATORY DISEASES Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17762325 TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS Non-Final OA ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
18629321 SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Non-Final OA EPIGENETIX, INC.
18615334 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA Non-Final OA Poolbeg Pharma (UK) Limited
18596840 METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE Non-Final OA Lake O'Hara LLC
18514875 METHODS FOR AMELIORATING AND PREVENTING AGE-RELATED MUSCLE DEGENERATION Non-Final OA NANJING NUTRABUILDING BIO-TECH CO., LTD.
18419894 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF Non-Final OA Celgene Corporation
18562768 BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION Non-Final OA BELITE BIO, LLC
18562676 COMPOUNDS FOR DEGRADATION OF CYCLIN-DEPENDENT KINASE 7(CDK7) Non-Final OA QURIENT CO., LTD.
18555467 COCRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Non-Final OA Loxo Oncology, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month